3078.15 -18.30 (-0.59%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
3075.15
Today’s High
3104.8
52 Week Low
2835.0
52 Week High
3784.0
3082.40 -19.20 (-0.62%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
3075.65
Today’s High
3103.25
52 Week Low
2828
52 Week High
3786
Key Metrics
- Market Cap (In Cr) 37302.49
- Beta 0.54
- Div. Yield (%) 0.13
- P/B 4.32
- TTM P/E 35.89
- Peg Ratio 2.31
- Sector P/E 27.15
- D/E 0.21
- Open Price 3075.15
- Prev Close 3096.45
Analysis
Price Analysis
-
1 Week1.27%
-
3 Months2.8%
-
6 Month0.19%
-
YTD-13.91%
-
1 Year-9.28%
Risk Meter
- 19% Low risk
- 19% Moderate risk
- 19% Balanced Risk
- 19% High risk
- 19% Extreme risk
Recos
23 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- Strong Sell
- 3
- Sell
- 3
- Hold
- 7
- Buy
- 6
- Strong Buy
- 4
Alkem Laboratories News
These 3 companies give the most number of billionaires in India. Check list
3 min read . 21 Sep 2022
Stocks to Watch: SBI, Tech Mahindra, RIL, Bank of Baroda, Airtel, Tata Motors
2 min read . 13 May 2022Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 10634.19
- Selling/ General/ Admin Expenses Total
- 4240.27
- Depreciation/ Amortization
- 303.96
- Other Operating Expenses Total
- 53.51
- Total Operating Expense
- 8862.68
- Operating Income
- 1771.51
- Net Income Before Taxes
- 1844.28
- Net Income
- 1645.62
- Diluted Normalized EPS
- 137.57
- Period
- 2022
- Total Assets
- 14069.19
- Total Liabilities
- 5431.29
- Total Equity
- 8637.9
- Tangible Book Valueper Share Common Eq
- 682.69
- Period
- 2022
- Cashfrom Operating Activities
- 1111.02
- Cashfrom Investing Activities
- -1435.13
- Cashfrom Financing Activities
- 379.57
- Net Changein Cash
- 57.96
- Period
- 2021
- Total Revenue
- 8865.01
- Selling/ General/ Admin Expenses Total
- 3277.01
- Depreciation/ Amortization
- 274.58
- Other Operating Expenses Total
- 54.83
- Total Operating Expense
- 7195.53
- Operating Income
- 1669.48
- Net Income Before Taxes
- 1842.1
- Net Income
- 1585.02
- Diluted Normalized EPS
- 129.72
- Period
- 2021
- Total Assets
- 11519.26
- Total Liabilities
- 4142.53
- Total Equity
- 7376.73
- Tangible Book Valueper Share Common Eq
- 576.83
- Period
- 2021
- Cashfrom Operating Activities
- 1264.9
- Cashfrom Investing Activities
- -998.54
- Cashfrom Financing Activities
- -271.75
- Net Changein Cash
- -1.72
- Period
- 2020
- Total Revenue
- 8344.36
- Selling/ General/ Admin Expenses Total
- 3310.36
- Depreciation/ Amortization
- 252.76
- Other Operating Expenses Total
- 71.43
- Total Operating Expense
- 7057.36
- Operating Income
- 1287
- Net Income Before Taxes
- 1259.79
- Net Income
- 1127.07
- Diluted Normalized EPS
- 94.42
- Period
- 2020
- Total Assets
- 9945.54
- Total Liabilities
- 3784.87
- Total Equity
- 6160.67
- Tangible Book Valueper Share Common Eq
- 473.7
- Period
- 2020
- Cashfrom Operating Activities
- 585.08
- Cashfrom Investing Activities
- -741.35
- Cashfrom Financing Activities
- 79.15
- Net Changein Cash
- -73.11
- Period
- 2019
- Total Revenue
- 7357.19
- Selling/ General/ Admin Expenses Total
- 3082.65
- Depreciation/ Amortization
- 193.18
- Other Operating Expenses Total
- 58.7
- Total Operating Expense
- 6396.56
- Operating Income
- 960.63
- Net Income Before Taxes
- 954.66
- Net Income
- 760.51
- Diluted Normalized EPS
- 63.98
- Period
- 2019
- Total Assets
- 8208.19
- Total Liabilities
- 2768.85
- Total Equity
- 5439.34
- Tangible Book Valueper Share Common Eq
- 419.4
- Period
- 2019
- Cashfrom Operating Activities
- 779.65
- Cashfrom Investing Activities
- -316.39
- Cashfrom Financing Activities
- -378.94
- Net Changein Cash
- 82.34
- Period
- 2018
- Total Revenue
- 6431.18
- Selling/ General/ Admin Expenses Total
- 2628.97
- Depreciation/ Amortization
- 143.03
- Other Operating Expenses Total
- 143.33
- Total Operating Expense
- 5539.17
- Operating Income
- 892.01
- Net Income Before Taxes
- 925.98
- Net Income
- 630.94
- Diluted Normalized EPS
- 52.74
- Period
- 2018
- Total Assets
- 7665.63
- Total Liabilities
- 2801.86
- Total Equity
- 4863.77
- Tangible Book Valueper Share Common Eq
- 372.47
- Period
- 2018
- Cashfrom Operating Activities
- 266.04
- Cashfrom Investing Activities
- -357.23
- Cashfrom Financing Activities
- 84.56
- Net Changein Cash
- 0.08
- Period
- 2017
- Total Revenue
- 5852.5
- Selling/ General/ Admin Expenses Total
- 2253.72
- Depreciation/ Amortization
- 101.17
- Other Operating Expenses Total
- 97.24
- Total Operating Expense
- 4951.96
- Operating Income
- 900.54
- Net Income Before Taxes
- 964.63
- Net Income
- 892.03
- Diluted Normalized EPS
- 74.76
- Period
- 2017
- Total Assets
- 6568.05
- Total Liabilities
- 2100.41
- Total Equity
- 4467.64
- Tangible Book Valueper Share Common Eq
- 339.99
- Period
- 2017
- Cashfrom Operating Activities
- 471.14
- Cashfrom Investing Activities
- -285.93
- Cashfrom Financing Activities
- -137.88
- Net Changein Cash
- 39.6
- Period
- 2022-09-30
- Total Revenue
- 3079.37
- Selling/ General/ Admin Expenses Total
- 570.85
- Depreciation/ Amortization
- 77.4
- Other Operating Expenses Total
- 747.66
- Total Operating Expense
- 2702.86
- Operating Income
- 376.51
- Net Income Before Taxes
- 402.33
- Net Income
- 330.84
- Diluted Normalized EPS
- 27.67
- Period
- 2022-09-30
- Total Assets
- 13869.23
- Total Liabilities
- 4727.53
- Total Equity
- 9141.7
- Tangible Book Valueper Share Common Eq
- 723.74
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 563.73
- Cashfrom Investing Activities
- 338.63
- Cashfrom Financing Activities
- -888.56
- Net Changein Cash
- 9.02
- Period
- 2022-06-30
- Total Revenue
- 2576.38
- Selling/ General/ Admin Expenses Total
- 532.15
- Depreciation/ Amortization
- 76.26
- Other Operating Expenses Total
- 745.56
- Total Operating Expense
- 2449.4
- Operating Income
- 126.98
- Net Income Before Taxes
- 151.89
- Net Income
- 127.64
- Diluted Normalized EPS
- 10.68
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 2483.86
- Selling/ General/ Admin Expenses Total
- 465.49
- Depreciation/ Amortization
- 83.14
- Other Operating Expenses Total
- 649.79
- Total Operating Expense
- 2229.77
- Operating Income
- 254.09
- Net Income Before Taxes
- 242.68
- Net Income
- 107.58
- Diluted Normalized EPS
- 9
- Period
- 2022-03-31
- Total Assets
- 14069.19
- Total Liabilities
- 5431.29
- Total Equity
- 8637.9
- Tangible Book Valueper Share Common Eq
- 682.69
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 1111.02
- Cashfrom Investing Activities
- -1435.13
- Cashfrom Financing Activities
- 379.57
- Net Changein Cash
- 57.96
- Period
- 2021-12-31
- Total Revenue
- 2618.98
- Selling/ General/ Admin Expenses Total
- 470.9
- Depreciation/ Amortization
- 77.46
- Other Operating Expenses Total
- 652.95
- Total Operating Expense
- 2197.99
- Operating Income
- 420.99
- Net Income Before Taxes
- 463.94
- Net Income
- 525.66
- Diluted Normalized EPS
- 43.96
- Period
- 2021-12-31
- Period
- 2021-12-31
- Period
- 2021-09-30
- Total Revenue
- 2799.99
- Selling/ General/ Admin Expenses Total
- 494.49
- Depreciation/ Amortization
- 72.83
- Other Operating Expenses Total
- 623.65
- Total Operating Expense
- 2248.44
- Operating Income
- 551.55
- Net Income Before Taxes
- 581.54
- Net Income
- 544.26
- Diluted Normalized EPS
- 45.52
- Period
- 2021-09-30
- Total Assets
- 12679.37
- Total Liabilities
- 4345.51
- Total Equity
- 8333.86
- Tangible Book Valueper Share Common Eq
- 649.57
- Period
- 2021-09-30
- Cashfrom Operating Activities
- 832.12
- Cashfrom Investing Activities
- -577.05
- Cashfrom Financing Activities
- -96.41
- Net Changein Cash
- 159.38
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day3122.41
- 10 Day3107.4
- 20 Day3127.96
- 50 Day3170.49
- 100 Day3134.22
- 300 Day3185.99
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Abbott India
- 20233
- 25.35
- 0.13
- 20895
- 15426.74
- 42624.83
- Zydus Lifesciences
- 405.8
- -4.3
- -1.05
- 487
- 319.4
- 41849.58
- Alkem Laboratories
- 3078.15
- -18.3
- -0.59
- 3784
- 2835
- 37302.49
- Lupin
- 768.6
- 1.5
- 0.2
- 972.5
- 583.05
- 35019.07
- Biocon
- 275.6
- 2.3
- 0.84
- 410.5
- 258.3
- 33340.73
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Abbott India
- 53.37
- 15.12
- 27.07
- 14.45
- Zydus Lifesciences
- 19.68
- 2.49
- 17
- 13.51
- Alkem Laboratories
- 22.68
- 4.32
- 18.92
- 14.07
- Lupin
- 146.27
- 2.88
- 0.08
- 0.13
- Biocon
- 46.83
- 3.98
- 10.68
- 12.71
Shareholding
- Category
- Percentage
- No. of shares
- Promoter & Promoter Group Shareholding
- 57.16%
- 68,342,509
- Sarandhar Singh* (Please refer notes)
- 21.08%
- 25,205,800
- Dhananjay Kumar Singh
- 7.96%
- 9,518,565
- Basudeo Narain Singh
- 7.24%
- 8,662,100
- Mritunjay Kumar Singh
- 6.39%
- 7,642,100
- Jayanti Sinha
- 4.3%
- 5,138,220
- Seema Singh
- 2.46%
- 2,937,740
- Archana Singh
- 2%
- 2,394,050
- Aniruddha Singh & (Please refer notes)
- 1.01%
- 1,208,971
- Divya Singh
- 1.01%
- 1,208,971
- Meghna Singh
- 1.01%
- 1,208,650
- Shrey Shree Anant Singh
- 1%
- 1,195,650
- Madhurima Singh & (Please refer notes)
- 0.76%
- 908,694
- Raj Kumar Singh
- 0.45%
- 538,038
- Balmiki Prasad Singh # (please refer notes)
- 0.1%
- 122,111
- Sandeep Singh# (please refer notes)
- 0.09%
- 112,357
- Srinivas Singh# (please refer notes)
- 0.07%
- 81,100
- Sarvesh Singh# (please refer notes)
- 0.07%
- 79,800
- Sarandhar Singh# (please refer notes)
- 0.07%
- 79,800
- Satish Kumar Singh# (please refer notes)
- 0.06%
- 71,934
- Madhurima Singh @ (Please refer notes)
- 0.02%
- 20,055
- Inderjit Kaur Arora# (please refer notes)
- 0.01%
- 7,800
- Annapurna Singh # (please refer notes)
- 0%
- 1
- Manju Singh # (please refer notes)
- 0%
- 1
- Premlata Singh # (please refer notes)
- 0%
- 1
- Public Shareholding
- 42.84%
- 51,222,491
- Kishor Kumar Singh
- 2.86%
- 3,423,312
- Rajesh Kumar
- 2.71%
- 3,239,535
- Rajeev Ranjan
- 2.54%
- 3,040,342
- Alok Kumar
- 2.31%
- 2,764,719
- Ashok Kumar
- 2.31%
- 2,760,079
- Deepak Kumar Singh
- 2.3%
- 2,755,095
- Nawal Kishore Singh
- 2.21%
- 2,644,649
- Others
- 3.55%
- 4,230,669
- Dsp Midcap Fund
- 2.35%
- 2,806,183
- Icici Prudential Pharma Healthcare And Diaganostics (P.H.D) Fund
- 2.21%
- 2,639,464
- Others
- 4.85%
- 5,818,848
- Life Insurance Corporation Of India
- 3.94%
- 4,716,581
- Hdfc Life Insurance Company Limited
- 1.11%
- 1,324,424
- Others
- 0.79%
- 939,828
- Others
- 4.46%
- 5,328,840
- Others
- 1.49%
- 1,778,039
- Others
- 0.24%
- 288,398
- Others
- 0.23%
- 280,408
- Clearing Members
- 0.08%
- 98,695
- HUF
- 0.05%
- 61,470
- LLP
- 0.01%
- 7,497
- Trusts
- 0%
- 2,199
- Others
- 0.13%
- 150,431
- Others
- 0.1%
- 121,803
- Others
- 0%
- 750
- Others
- 0%
- 218
- Others
- 0%
- 14
- Others
- 0%
- 1
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 11-Nov-22
- Quarterly Results
- 05-Aug-22
- Quarterly Results
- 13-May-22
- Audited Results & Final Dividend
- 04-Feb-22
- Quarterly Results & Interim Dividend
- 12-Nov-21
- Quarterly Results
- 06-Aug-21
- Quarterly Results
- 25-May-21
- Audited Results & Final Dividend
- 05-Feb-21
- Quarterly Results & Interim Dividend
- Meeting Date
- Announced on
- Purpose
- 25-Aug-22
- 13-May-22
- AGM
- 14-Feb-22
- 11-Jan-22
- POM
- 27-Aug-21
- 25-May-21
- AGM
- 26-Mar-21
- 22-Feb-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 13-May-22
- 10-Aug-22
- 08-Aug-22
- 4
- 24-Jan-22
- 12-Feb-22
- 10-Feb-22
- 30
- 25-May-21
- 10-Aug-21
- 09-Aug-21
- 5
- 27-Jan-21
- 13-Feb-21
- 11-Feb-21
- 25
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Alkem Laboratories
- Industry Biotechnology & Drugs
- ISIN INE540L01014
- BSE Code 539523
- NSE Code ALKEM
Alkem Laboratories Limited is a pharmaceutical company. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company operates through pharmaceuticals segment. The Company produces generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and approximately 50 countries internationally. The Company offers its products across various therapeutic areas, such as anti-infective, dermatology, diabetology, cardiology, gastroenterology, osteoporosis, Rheumatology, central nervous system (CNS), oncology, urology and gynecology. The Company offers its products under various brands, including Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Gemcal, Taxim, Sumo, Maxvoid Plus, Tamsukem Plus and Neurokem NT. The Company has approximately 20 manufacturing facilities, of which 18 manufacturing facilities are located in India and two in the United States.
MANAGEMENT
- Basudeo Singh Executive Chairman of the Board
- Rajesh Dubey Chief Financial Officer, President - Finance
- Manish Narang President - Legal, Chief Compliance Officer, Company Secretary
- Sandeep Singh Managing Director, Executive Director
- Madhurima Singh Executive Director
- Mritunjay Singh Executive Director
- Sarvesh Singh Executive Director
- Srinivas Singh Executive Director
Company Summary
ALKEM LABORATORIES SUMMARY
Alkem Laboratories is trading 0.59% lower at Rs 3078.15 as compared to its last closing price. Alkem Laboratories has been trading in the price range of 3104.8 & 3075.15. Alkem Laboratories has given -13.91% in this year & 1.27% in the last 5 days.
Alkem Laboratories has TTM P/E ratio 35.89 as compared to the sector P/E of 27.15. There are 23 analysts who have initiated coverage on Alkem Laboratories. There are 4 analysts who have given it a strong buy rating & 6 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.
The company posted a net profit of 330.84 Crores in its last quarter.
Listed peers of Alkem Laboratories include Abbott India (0.13%), Zydus Lifesciences (-1.05%), Alkem Laboratories (-0.59%) etc.
FAQs about Alkem Laboratories
Alkem Laboratories is trading at 3078.15 as on 7 Dec, 2022 3:29:00 PM. This is -0.59% lower as compared to its previous closing price of 3096.45
The market capitalization of Alkem Laboratories is 37302.49 Cr as on 7 Dec, 2022 3:29:00 PM.
The average broker rating on Alkem Laboratories is Hold. The breakup of analyst rating is given below -
- 3 analysts have given a strong sell rating
- 3 analysts have given a sell rating
- 7 analysts have given a hold rating
- 6 analysts have given a buy rating
- 4 analysts have given a strong buy rating
The 52 wk high for Alkem Laboratories is 3784.0 whereas the 52 wk low is 2835.0
Alkem Laboratories can be analyzed on the following key metrics -
- TTM P/E: 35.89
- Sector P/E: 27.15
- Dividend Yield: 0.13%
- D/E ratio: -
Alkem Laboratories reported a net profit of 1645.62 Cr in 2022.
